Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Assets (2016 - 2025)

Historic Assets for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $1.3 billion.

  • Agios Pharmaceuticals' Assets fell 2200.42% to $1.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year decrease of 2200.42%. This contributed to the annual value of $1.3 billion for FY2025, which is 2200.42% down from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Assets of $1.3 billion as of Q4 2025, which was down 2200.42% from $1.4 billion recorded in Q3 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Assets peaked at $2.5 billion during Q1 2021, and registered a low of $773.1 million during Q2 2024.
  • For the 5-year period, Agios Pharmaceuticals' Assets averaged around $1.4 billion, with its median value being $1.3 billion (2022).
  • In the last 5 years, Agios Pharmaceuticals' Assets surged by 21115.62% in 2021 and then tumbled by 4631.73% in 2022.
  • Over the past 5 years, Agios Pharmaceuticals' Assets (Quarter) stood at $1.4 billion in 2021, then decreased by 13.84% to $1.2 billion in 2022, then fell by 24.35% to $937.1 million in 2023, then surged by 77.48% to $1.7 billion in 2024, then decreased by 22.0% to $1.3 billion in 2025.
  • Its Assets stands at $1.3 billion for Q4 2025, versus $1.4 billion for Q3 2025 and $1.5 billion for Q2 2025.